Funded by: FundRef https://doi.org/10.13039/100000060, U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID);
Award ID: HHSN272200800056C
Award ID: HHSN272201000006I
Award ID: HHSN272201200003I
Award ID: HHSN272200800056C
Award ID: HHSN272201000006I
Award ID: HHSN272201200003I
Award ID: HHSN272200800056C
Award ID: HHSN272201000006I
Award ID: HHSN272201200003I
Award ID: HHSN272200800056C
Award ID: HHSN272201000006I
Award ID: HHSN272201200003I
Award ID: HHSN272200800056C
Award ID: HHSN272201000006I
Award ID: HHSN272201200003I
Award ID: HHSN272200800056C
Award ID: HHSN272201000006I
Award ID: HHSN272201200003I
Award ID: HHSN272200800056C
Award ID: HHSN272201000006I
Award ID: HHSN272201200003I
Award ID: HHSN272200800056C
Award ID: HHSN272201000006I
Award ID: HHSN272201200003I
Award ID: HHSN272200800056C
Award ID: HHSN272201000006I
Award ID: HHSN272201200003I
Award ID: HHSN272200800056C
Award ID: HHSN272201000006I
Award ID: HHSN272201200003I
Award ID: HHSN272200800056C
Award ID: HHSN272201000006I
Award ID: HHSN272201200003I
Award ID: HHSN272200800056C
Award ID: HHSN272201000006I
Award ID: HHSN272201200003I
Award ID: HHSN272200800056C
Award ID: HHSN272201000006I
Award ID: HHSN272201200003I
Award ID: HHSN272200800056C
Award ID: HHSN272201000006I
Award ID: HHSN272201200003I
Award ID: HHSN272200800056C
Award ID: HHSN272201000006I
Award ID: HHSN272201200003I
Award ID: HHSN272200800056C
Award ID: HHSN272201000006I
Award ID: HHSN272201200003I
Award ID: HHSN272200800056C
Award ID: HHSN272201000006I
Award ID: HHSN272201200003I
Award ID: HHSN272200800056C
Award ID: HHSN272201000006I
Award ID: HHSN272201200003I
Award ID: HHSN272200800056C
Award ID: HHSN272201000006I
Award ID: HHSN272201200003I
Award ID: HHSN272200800056C
Award ID: HHSN272201000006I
Award ID: HHSN272201200003I
Award ID: HHSN272200800056C
Award ID: HHSN272201000006I
Award ID: HHSN272201200003I
Award ID: HHSN272200800056C
Award ID: HHSN272201000006I
Award ID: HHSN272201200003I
Award ID: HHSN272200800056C
Award ID: HHSN272201000006I
Award ID: HHSN272201200003I
Award ID: HHSN272200800056C
Award ID: HHSN272201000006I
Award ID: HHSN272201200003I
Award ID: HHSN272200800056C
Award ID: HHSN272201000006I
Award ID: HHSN272201200003I
Award ID: HHSN272200800056C
Award ID: HHSN272201000006I
Award ID: HHSN272201200003I
Award ID: HHSN272200800056C
Award ID: HHSN272201000006I
Award ID: HHSN272201200003I
Award Recipient
:
Ramon Roozendaal
Jenny Hendriks
Thierry van Effelterre
Bart Spiessens
Liesbeth Dekking
Laura Solforosi
Dominika Czapska-Casey
Viki Bockstal
Jeroen Stoop
Daniel Splinter
Sarah Janssen
Ben van Baelen
Nadia Verbruggen
Jan Serroyen
Eline Dekeyster
Ariane Volkmann
Yvonne Wollmann
Ricardo Carrion Jr.
Cynthia Robinson
Maarten Leyssen
Macaya Douoguih
Kerstin Luhn
Jerry Sadoff
An Vandebosch
Hanneke Schuitemaker
Roland Zahn
Benoit Callendret
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: EBL1001 and EBL1004 received funding from the Innovative Medicines Initiative 2 Joint
Undertaking under grant agreement number 115854. This Joint Undertaking receives support
from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Association.
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: EBL1001 and EBL1004 received funding from the Innovative Medicines Initiative 2 Joint
Undertaking under grant agreement number 115854. This Joint Undertaking receives support
from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Association.
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: EBL1001 and EBL1004 received funding from the Innovative Medicines Initiative 2 Joint
Undertaking under grant agreement number 115854. This Joint Undertaking receives support
from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Association.
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: EBL1001 and EBL1004 received funding from the Innovative Medicines Initiative 2 Joint
Undertaking under grant agreement number 115854. This Joint Undertaking receives support
from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Association.
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: EBL1001 and EBL1004 received funding from the Innovative Medicines Initiative 2 Joint
Undertaking under grant agreement number 115854. This Joint Undertaking receives support
from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Association.
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: EBL1001 and EBL1004 received funding from the Innovative Medicines Initiative 2 Joint
Undertaking under grant agreement number 115854. This Joint Undertaking receives support
from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Association.
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: EBL1001 and EBL1004 received funding from the Innovative Medicines Initiative 2 Joint
Undertaking under grant agreement number 115854. This Joint Undertaking receives support
from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Association.
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: EBL1001 and EBL1004 received funding from the Innovative Medicines Initiative 2 Joint
Undertaking under grant agreement number 115854. This Joint Undertaking receives support
from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Association.
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: EBL1001 and EBL1004 received funding from the Innovative Medicines Initiative 2 Joint
Undertaking under grant agreement number 115854. This Joint Undertaking receives support
from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Association.
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: EBL1001 and EBL1004 received funding from the Innovative Medicines Initiative 2 Joint
Undertaking under grant agreement number 115854. This Joint Undertaking receives support
from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Association.
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: EBL1001 and EBL1004 received funding from the Innovative Medicines Initiative 2 Joint
Undertaking under grant agreement number 115854. This Joint Undertaking receives support
from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Association.
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: EBL1001 and EBL1004 received funding from the Innovative Medicines Initiative 2 Joint
Undertaking under grant agreement number 115854. This Joint Undertaking receives support
from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Association.
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: EBL1001 and EBL1004 received funding from the Innovative Medicines Initiative 2 Joint
Undertaking under grant agreement number 115854. This Joint Undertaking receives support
from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Association.
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: EBL1001 and EBL1004 received funding from the Innovative Medicines Initiative 2 Joint
Undertaking under grant agreement number 115854. This Joint Undertaking receives support
from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Association.
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: EBL1001 and EBL1004 received funding from the Innovative Medicines Initiative 2 Joint
Undertaking under grant agreement number 115854. This Joint Undertaking receives support
from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Association.
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: EBL1001 and EBL1004 received funding from the Innovative Medicines Initiative 2 Joint
Undertaking under grant agreement number 115854. This Joint Undertaking receives support
from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Association.
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: EBL1001 and EBL1004 received funding from the Innovative Medicines Initiative 2 Joint
Undertaking under grant agreement number 115854. This Joint Undertaking receives support
from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Association.
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: EBL1001 and EBL1004 received funding from the Innovative Medicines Initiative 2 Joint
Undertaking under grant agreement number 115854. This Joint Undertaking receives support
from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Association.
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: EBL1001 and EBL1004 received funding from the Innovative Medicines Initiative 2 Joint
Undertaking under grant agreement number 115854. This Joint Undertaking receives support
from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Association.
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: EBL1001 and EBL1004 received funding from the Innovative Medicines Initiative 2 Joint
Undertaking under grant agreement number 115854. This Joint Undertaking receives support
from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Association.
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: EBL1001 and EBL1004 received funding from the Innovative Medicines Initiative 2 Joint
Undertaking under grant agreement number 115854. This Joint Undertaking receives support
from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Association.
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: EBL1001 and EBL1004 received funding from the Innovative Medicines Initiative 2 Joint
Undertaking under grant agreement number 115854. This Joint Undertaking receives support
from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Association.
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: EBL1001 and EBL1004 received funding from the Innovative Medicines Initiative 2 Joint
Undertaking under grant agreement number 115854. This Joint Undertaking receives support
from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Association.
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: EBL1001 and EBL1004 received funding from the Innovative Medicines Initiative 2 Joint
Undertaking under grant agreement number 115854. This Joint Undertaking receives support
from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Association.
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: EBL1001 and EBL1004 received funding from the Innovative Medicines Initiative 2 Joint
Undertaking under grant agreement number 115854. This Joint Undertaking receives support
from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Association.
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: EBL1001 and EBL1004 received funding from the Innovative Medicines Initiative 2 Joint
Undertaking under grant agreement number 115854. This Joint Undertaking receives support
from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Association.
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and
Infectious Diseases (NIAID)
Funded by: EBL1001 and EBL1004 received funding from the Innovative Medicines Initiative 2 Joint
Undertaking under grant agreement number 115854. This Joint Undertaking receives support
from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Association.